Pharmaceuticals
Korea biotech start-up gets $44.5m pre-IPO round
Korea’s Standigm, which provides artificial intelligence (AI) systems to biotech operators, has raised a $44.5 billion pre-IPO round led by SKS Private Equity and Daishin Privat Equity.
PE-backed SciClone achieves $1.6b market cap on HK re-listing
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed raises $800m for Asia life sciences fund
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
China’s Clover Biopharmaceuticals gets $230m Series C
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
China’s Regor Therapeutics raises $90m Series B
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.
Chinese virotherapy specialist Binhui Biotech raises $93m
Wuhan-based Binhui Biotech has raised RMB600 million ($93 million) in Series C funding led by Shenzhen-based Share Capital. Other investors include CICC Capital, Vertex Ventures China and Qianhai FOF under Shenzhen Capital Group.
China's Cloopen, Adagene complete strong US IPOs
Cloud services provider Cloopen and biotech developer Adagene, both backed by Sequoia Capital China, have raised a combined $460 million in their US IPOs.
Sequoia, Tencent lead Series E for China’s Miaoshou Doctor
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB3 billion ($466 million) in Series E funding led by Sequoia Capital China and Tencent Holdings.
Advent buys majority stake in India's ZCL, MSPEA exits
Advent International has agreed to acquire Indian pharmaceuticals supplier ZCL Chemicals, setting up a minority exit for Morgan Stanley Private Equity Asia (MSPEA).
Carlyle, Brighton Park invest $200m in India's Indegene
The Carlyle Group and US GP Brighton Park Capital have committed a combined $200 million to Indegene, an Indian technology provider for the healthcare and life sciences industries.
Lilly Asia Ventures raises $1.35b for healthcare funds
Lilly Asia Ventures (LAV) has raised $1.35 billion for its latest healthcare fund, having introduced a $450 million opportunity vehicle that sits alongside a core pool of $900 million.
General Atlantic backs Indonesia biotech developer
General Atlantic has invested $55 million in Kalbe Genexine Biologics, an Indonesia-based drug developer focusing on Southeast Asia.
Fund focus: LPs flock to Lake Bleu’s late show
Lake Bleu Capital leveraged a lift in Chinese healthcare sentiment to raise $560 million for a fund that will target late-stage healthcare investments
Deal focus: Monetizing mice
ORI Capital’s 2.8x return on its investment in Kymab was in part based on helping the company make the transition from antibody-based discovery platform to drug development engine
Lake Bleu raises $560m for Asia pre-IPO healthcare fund
Lake Bleu Capital, a Hong Kong-based private equity investor focused on healthcare, has raised $560 million for a pre-IPO fund targeting Asia with an emphasis on Greater China.
China’s CICC raises $650m for biomedical fund
CICC Capital has reached a second close of RMB4.2 billion ($650 million) on its latest healthcare fund - the first in China to receive fast-track approval for its role in addressing COVID-19.
Hong Kong's ORI hits first close on Fund II, exits Kymab
Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.
Sequoia leads $150m Series B for China's Visen Pharma
China’s Visen Pharmaceuticals, a drug developer targeting glandular conditions such as dwarfism and growth deficiency has raised a $150 million Series B round led by Sequoia Capital China.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
J-Star acquires Japan drug wholesaler Genex
Japanese private equity firm J-Star has taken a controlling stake in local pharmaceuticals wholesaler Genex for an undisclosed sum.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
LAV, Arch lead $100m round for China's SciNeuro
SciNeuro Pharmaceuticals, a China and US-based drug developer specializing in treatments for central nervous system (CNS) disorders, has announced its formal launch with a $100 million funding round.
Everstone buys Indian pharma ingredients player
Everstone Group has acquired a controlling stake in Calibre, an Indian ingredients supplier for the pharmaceutical and nutrition industries, for an undisclosed sum.